OpenAI has made its largest investment in Merge Labs, a brain-computer interface startup co-founded by its own CEO Sam Altman. The $252 million seed round values the company at $850 million, with Bain Capital leading and Valve co-founder Gabe Newell also participating.
Merge Labs aims to develop non-invasive BCIs using molecules instead of electrodes, with ultrasound for data transmission—avoiding surgical implants entirely. "We envision future BCIs that are equal parts biology, device, and AI in a form factor that we ourselves want to use," the company stated. Co-founders include neuroscience researchers Mikhail Shapiro, Tyson Aflalo, and Sumner Norman, alongside tech entrepreneurs Alex Blania and Sandro Herbig.
The funding puts Merge among the best-capitalized BCI startups, second only to Neuralink's $650 million Series E at $9 billion valuation. However, Merge concedes its technology may take "decades rather than years" to realize. The investment raises conflict-of-interest questions given Altman's dual role as OpenAI CEO and Merge co-founder.
